User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Pharmacogenetic associations with cytochrome P450 in antiretroviral therapy: what does the future hold?

Primary tabs

download
  • Open access
  • PDF
  • 1.29 M
Stillemans, Gabriel [UCL] Belkhir, Leïla [UCL] Hesselink, Dennis A Haufroid, Vincent [UCL] Elens, Laure [UCL]

Several antiretroviral drugs used to treat infection with the human immunodeficiency virus (HIV) are substrates of enzymes belonging to the cytochrome P450 (CYP) superfamily, which are polymorphically expressed. It may therefore be useful to take into account the genetic variation in these enzymes to predict the likelihood of anti-HIV treatment success, toxicity and the potential for drug-drug interactions. Areas covered: In this manuscript, the authors discuss the current state of knowledge regarding pharmacogenetic associations between CYP and all major antiretrovirals, as well as the importance of these associations. Expert opinion: While many pharmacogenetic associations for CYP have been described in the literature, replication studies are sometimes lacking. The implementation of this knowledge in clinical practice also remains difficult. Further efforts are required both to expand this field of knowledge and to enable its use in everyday clinical practice.

Document type Article de périodique (Journal article) – Synthèse de littérature
Access type Accès libre
Publication date 2018
Language Anglais
Journal information "Expert opinion on drug metabolism & toxicology" - Vol. 14, no. 6, p. 601-611 (2018)
Peer reviewed yes
Publisher Informa Healthcare ((United Kingdom) London)
issn 1742-5255
e-issn 1744-7607
Publication status Publié
Affiliations UCL - SSS/LDRI - Louvain Drug Research Institute
UCL - SSS/IREC/SLUC - Pôle St.-Luc
UCL - SSS/IREC/LTAP - Louvain Centre for Toxicology and Applied Pharmacology
UCL - (SLuc) Service de biochimie médicale
UCL - (SLuc) Service de médecine interne et maladies infectieuses (MIMI)
MESH Subject Anti-HIV Agents ; Cytochrome P-450 Enzyme System ; Drug Interactions ; Genetic Variation ; HIV Infections ; Humans ; Pharmacogenetics
Keywords Antiretroviral ; cytochrome P450 ; human immunodeficiency virus ; non-nucleoside reverse transcriptase inhibitor ; pharmacogenetics ; pharmacogenomics ; protease inhibitor
Links
  1. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies, 10.1016/s0140-6736(08)61113-7
  2. Samji Hasina, Cescon Angela, Hogg Robert S., Modur Sharada P., Althoff Keri N., Buchacz Kate, Burchell Ann N., Cohen Mardge, Gebo Kelly A., Gill M. John, Justice Amy, Kirk Gregory, Klein Marina B., Korthuis P. Todd, Martin Jeff, Napravnik Sonia, Rourke Sean B., Sterling Timothy R., Silverberg Michael J., Deeks Stephen, Jacobson Lisa P., Bosch Ronald J., Kitahata Mari M., Goedert James J., Moore Richard, Gange Stephen J., , Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada, 10.1371/journal.pone.0081355
  3. Cohen Myron S., Chen Ying Q., McCauley Marybeth, Gamble Theresa, Hosseinipour Mina C., Kumarasamy Nagalingeswaran, Hakim James G., Kumwenda Johnstone, Grinsztejn Beatriz, Pilotto Jose H.S., Godbole Sheela V., Chariyalertsak Suwat, Santos Breno R., Mayer Kenneth H., Hoffman Irving F., Eshleman Susan H., Piwowar-Manning Estelle, Cottle Leslie, Zhang Xinyi C., Makhema Joseph, Mills Lisa A., Panchia Ravindre, Faesen Sharlaa, Eron Joseph, Gallant Joel, Havlir Diane, Swindells Susan, Elharrar Vanessa, Burns David, Taha Taha E., Nielsen-Saines Karin, Celentano David D., Essex Max, Hudelson Sarah E., Redd Andrew D., Fleming Thomas R., Antiretroviral Therapy for the Prevention of HIV-1 Transmission, 10.1056/nejmoa1600693
  4. Lek Monkol, , Karczewski Konrad J., Minikel Eric V., Samocha Kaitlin E., Banks Eric, Fennell Timothy, O’Donnell-Luria Anne H., Ware James S., Hill Andrew J., Cummings Beryl B., Tukiainen Taru, Birnbaum Daniel P., Kosmicki Jack A., Duncan Laramie E., Estrada Karol, Zhao Fengmei, Zou James, Pierce-Hoffman Emma, Berghout Joanne, Cooper David N., Deflaux Nicole, DePristo Mark, Do Ron, Flannick Jason, Fromer Menachem, Gauthier Laura, Goldstein Jackie, Gupta Namrata, Howrigan Daniel, Kiezun Adam, Kurki Mitja I., Moonshine Ami Levy, Natarajan Pradeep, Orozco Lorena, Peloso Gina M., Poplin Ryan, Rivas Manuel A., Ruano-Rubio Valentin, Rose Samuel A., Ruderfer Douglas M., Shakir Khalid, Stenson Peter D., Stevens Christine, Thomas Brett P., Tiao Grace, Tusie-Luna Maria T., Weisburd Ben, Won Hong-Hee, Yu Dongmei, Altshuler David M., Ardissino Diego, Boehnke Michael, Danesh John, Donnelly Stacey, Elosua Roberto, Florez Jose C., Gabriel Stacey B., Getz Gad, Glatt Stephen J., Hultman Christina M., Kathiresan Sekar, Laakso Markku, McCarroll Steven, McCarthy Mark I., McGovern Dermot, McPherson Ruth, Neale Benjamin M., Palotie Aarno, Purcell Shaun M., Saleheen Danish, Scharf Jeremiah M., Sklar Pamela, Sullivan Patrick F., Tuomilehto Jaakko, Tsuang Ming T., Watkins Hugh C., Wilson James G., Daly Mark J., MacArthur Daniel G., Analysis of protein-coding genetic variation in 60,706 humans, 10.1038/nature19057
  5. Hofmann M. H., Blievernicht J. K., Klein K., Saussele T., Schaeffeler E., Schwab M., Zanger U. M., Aberrant Splicing Caused by Single Nucleotide Polymorphism c.516G>T [Q172H], a Marker of CYP2B6*6, Is Responsible for Decreased Expression and Activity of CYP2B6 in Liver, 10.1124/jpet.107.133306
  6. Klein Kathrin, Lang Thomas, Saussele Tanja, Barbosa-Sicard Eduardo, Schunck Wolf-Hagen, Eichelbaum Michel, Schwab Matthias, Zanger Ulrich M., Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz : , 10.1097/01213011-200512000-00004
  7. Lamba V., Hepatic CYP2B6 Expression: Gender and Ethnic Differences and Relationship to CYP2B6 Genotype and CAR (Constitutive Androstane Receptor) Expression, 10.1124/jpet.103.054866
  8. Wang Danxin, Sadee Wolfgang, CYP3A4 intronic SNP rs35599367 (CYP3A4*22) alters RNA splicing : , 10.1097/fpc.0000000000000183
  9. Kuehl Peter, Zhang Jiong, Lin Yvonne, Lamba Jatinder, Assem Mahfoud, Schuetz John, Watkins Paul B., Daly Ann, Wrighton Steven A., Hall Stephen D., Maurel Patrick, Relling Mary, Brimer Cynthia, Yasuda Kazuto, Venkataramanan Raman, Strom Stephen, Thummel Kenneth, Boguski Mark S., Schuetz Erin, Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression, 10.1038/86882
  10. Gibbs Richard A., , Boerwinkle Eric, Doddapaneni Harsha, Han Yi, Korchina Viktoriya, Kovar Christie, Lee Sandra, Muzny Donna, Reid Jeffrey G., Zhu Yiming, Wang Jun, Chang Yuqi, Feng Qiang, Fang Xiaodong, Guo Xiaosen, Jian Min, Jiang Hui, Jin Xin, Lan Tianming, Li Guoqing, Li Jingxiang, Li Yingrui, Liu Shengmao, Liu Xiao, Lu Yao, Ma Xuedi, Tang Meifang, Wang Bo, Wang Guangbiao, Wu Honglong, Wu Renhua, Xu Xun, Yin Ye, Zhang Dandan, Zhang Wenwei, Zhao Jiao, Zhao Meiru, Zheng Xiaole, Lander Eric S., Altshuler David M., Gabriel Stacey B., Gupta Namrata, Gharani Neda, Toji Lorraine H., Gerry Norman P., Resch Alissa M., Flicek Paul, Barker Jonathan, Clarke Laura, Gil Laurent, Hunt Sarah E., Kelman Gavin, Kulesha Eugene, Leinonen Rasko, McLaren William M., Radhakrishnan Rajesh, Roa Asier, Smirnov Dmitriy, Smith Richard E., Streeter Ian, Thormann Anja, Toneva Iliana, Vaughan Brendan, Zheng-Bradley Xiangqun, Bentley David R., Grocock Russell, Humphray Sean, James Terena, Kingsbury Zoya, Lehrach Hans, Sudbrak Ralf, Albrecht Marcus W., Amstislavskiy Vyacheslav S., Borodina Tatiana A., Lienhard Matthias, Mertes Florian, Sultan Marc, Timmermann Bernd, Yaspo Marie-Laure, Mardis Elaine R., Wilson Richard K., Fulton Lucinda, Fulton Robert, Sherry Stephen T., Ananiev Victor, Belaia Zinaida, Beloslyudtsev Dimitriy, Bouk Nathan, Chen Chao, Church Deanna, Cohen Robert, Cook Charles, Garner John, Hefferon Timothy, Kimelman Mikhail, Liu Chunlei, Lopez John, Meric Peter, O’Sullivan Chris, Ostapchuk Yuri, Phan Lon, Ponomarov Sergiy, Schneider Valerie, Shekhtman Eugene, Sirotkin Karl, Slotta Douglas, Zhang Hua, McVean Gil A., Durbin Richard M., Balasubramaniam Senduran, Burton John, Danecek Petr, Keane Thomas M., Kolb-Kokocinski Anja, McCarthy Shane, Stalker James, Quail Michael, Schmidt Jeanette P., Davies Christopher J., Gollub Jeremy, Webster Teresa, Wong Brant, Zhan Yiping, Auton Adam, Campbell Christopher L., Kong Yu, Marcketta Anthony, Gibbs Richard A., Yu Fuli, Antunes Lilian, Bainbridge Matthew, Muzny Donna, Sabo Aniko, Huang Zhuoyi, Wang Jun, Coin Lachlan J. M., Fang Lin, Guo Xiaosen, Jin Xin, Li Guoqing, Li Qibin, Li Yingrui, Li Zhenyu, Lin Haoxiang, Liu Binghang, Luo Ruibang, Shao Haojing, Xie Yinlong, Ye Chen, Yu Chang, Zhang Fan, Zheng Hancheng, Zhu Hongmei, Alkan Can, Dal Elif, Kahveci Fatma, Marth Gabor T., Garrison Erik P., Kural Deniz, Lee Wan-Ping, Fung Leong Wen, Stromberg Michael, Ward Alistair N., Wu Jiantao, Zhang Mengyao, Daly Mark J., DePristo Mark A., Handsaker Robert E., Altshuler David M., Banks Eric, Bhatia Gaurav, del Angel Guillermo, Gabriel Stacey B., Genovese Giulio, Gupta Namrata, Li Heng, Kashin Seva, Lander Eric S., McCarroll Steven A., Nemesh James C., Poplin Ryan E., Yoon Seungtai C., Lihm Jayon, Makarov Vladimir, Clark Andrew G., Gottipati Srikanth, Keinan Alon, Rodriguez-Flores Juan L., Korbel Jan O., Rausch Tobias, Fritz Markus H., Stütz Adrian M., Flicek Paul, Beal Kathryn, Clarke Laura, Datta Avik, Herrero Javier, McLaren William M., Ritchie Graham R. S., Smith Richard E., Zerbino Daniel, Zheng-Bradley Xiangqun, Sabeti Pardis C., Shlyakhter Ilya, Schaffner Stephen F., Vitti Joseph, Cooper David N., Ball Edward V., Stenson Peter D., Bentley David R., Barnes Bret, Bauer Markus, Keira Cheetham R., Cox Anthony, Eberle Michael, Humphray Sean, Kahn Scott, Murray Lisa, Peden John, Shaw Richard, Kenny Eimear E., Batzer Mark A., Konkel Miriam K., Walker Jerilyn A., MacArthur Daniel G., Lek Monkol, Sudbrak Ralf, Amstislavskiy Vyacheslav S., Herwig Ralf, Mardis Elaine R., Ding Li, Koboldt Daniel C., Larson David, Ye Kai, Gravel Simon, Swaroop Anand, Chew Emily, Lappalainen Tuuli, Erlich Yaniv, Gymrek Melissa, Frederick Willems Thomas, Simpson Jared T., Shriver Mark D., Rosenfeld Jeffrey A., Bustamante Carlos D., Montgomery Stephen B., De La Vega Francisco M., Byrnes Jake K., Carroll Andrew W., DeGorter Marianne K., Lacroute Phil, Maples Brian K., Martin Alicia R., Moreno-Estrada Andres, Shringarpure Suyash S., Zakharia Fouad, Halperin Eran, Baran Yael, Lee Charles, Cerveira Eliza, Hwang Jaeho, Malhotra Ankit, Plewczynski Dariusz, Radew Kamen, Romanovitch Mallory, Zhang Chengsheng, Hyland Fiona C. L., Craig David W., Christoforides Alexis, Homer Nils, Izatt Tyler, Kurdoglu Ahmet A., Sinari Shripad A., Squire Kevin, Sherry Stephen T., Xiao Chunlin, Sebat Jonathan, Antaki Danny, Gujral Madhusudan, Noor Amina, Ye Kenny, Burchard Esteban G., Hernandez Ryan D., Gignoux Christopher R., Haussler David, Katzman Sol J., James Kent W., Howie Bryan, Ruiz-Linares Andres, Dermitzakis Emmanouil T., Devine Scott E., Abecasis Gonçalo R., Min Kang Hyun, Kidd Jeffrey M., Blackwell Tom, Caron Sean, Chen Wei, Emery Sarah, Fritsche Lars, Fuchsberger Christian, Jun Goo, Li Bingshan, Lyons Robert, Scheller Chris, Sidore Carlo, Song Shiya, Sliwerska Elzbieta, Taliun Daniel, Tan Adrian, Welch Ryan, Kate Wing Mary, Zhan Xiaowei, Awadalla Philip, Hodgkinson Alan, Li Yun, Shi Xinghua, Quitadamo Andrew, Lunter Gerton, McVean Gil A., Marchini Jonathan L., Myers Simon, Churchhouse Claire, Delaneau Olivier, Gupta-Hinch Anjali, Kretzschmar Warren, Iqbal Zamin, Mathieson Iain, Menelaou Androniki, Rimmer Andy, Xifara Dionysia K., Oleksyk Taras K., Fu Yunxin, Liu Xiaoming, Xiong Momiao, Jorde Lynn, Witherspoon David, Xing Jinchuan, Eichler Evan E., Browning Brian L., Browning Sharon R., Hormozdiari Fereydoun, Sudmant Peter H., Khurana Ekta, Durbin Richard M., Hurles Matthew E., Tyler-Smith Chris, Albers Cornelis A., Ayub Qasim, Balasubramaniam Senduran, Chen Yuan, Colonna Vincenza, Danecek Petr, Jostins Luke, Keane Thomas M., McCarthy Shane, Walter Klaudia, Xue Yali, Gerstein Mark B., Abyzov Alexej, Balasubramanian Suganthi, Chen Jieming, Clarke Declan, Fu Yao, Harmanci Arif O., Jin Mike, Lee Donghoon, Liu Jeremy, Jasmine Mu Xinmeng, Zhang Jing, Zhang Yan, Li Yingrui, Luo Ruibang, Zhu Hongmei, Alkan Can, Dal Elif, Kahveci Fatma, Marth Gabor T., Garrison Erik P., Kural Deniz, Lee Wan-Ping, Ward Alistair N., Wu Jiantao, Zhang Mengyao, McCarroll Steven A., Handsaker Robert E., Altshuler David M., Banks Eric, del Angel Guillermo, Genovese Giulio, Hartl Chris, Li Heng, Kashin Seva, Nemesh James C., Shakir Khalid, Yoon Seungtai C., Lihm Jayon, Makarov Vladimir, Degenhardt Jeremiah, Korbel Jan O., Fritz Markus H., Meiers Sascha, Raeder Benjamin, Rausch Tobias, Stütz Adrian M., Flicek Paul, Paolo Casale Francesco, Clarke Laura, Smith Richard E., Stegle Oliver, Zheng-Bradley Xiangqun, Bentley David R., Barnes Bret, Keira Cheetham R., Eberle Michael, Humphray Sean, Kahn Scott, Murray Lisa, Shaw Richard, Lameijer Eric-Wubbo, Batzer Mark A., Konkel Miriam K., Walker Jerilyn A., Ding Li, Hall Ira, Ye Kai, Lacroute Phil, Lee Charles, Cerveira Eliza, Malhotra Ankit, Hwang Jaeho, Plewczynski Dariusz, Radew Kamen, Romanovitch Mallory, Zhang Chengsheng, Craig David W., Homer Nils, Church Deanna, Xiao Chunlin, Sebat Jonathan, Antaki Danny, Bafna Vineet, Michaelson Jacob, Ye Kenny, Devine Scott E., Gardner Eugene J., Abecasis Gonçalo R., Kidd Jeffrey M., Mills Ryan E., Dayama Gargi, Emery Sarah, Jun Goo, Shi Xinghua, Quitadamo Andrew, Lunter Gerton, McVean Gil A., Chen Ken, Fan Xian, Chong Zechen, Chen Tenghui, Witherspoon David, Xing Jinchuan, Eichler Evan E., Chaisson Mark J., Hormozdiari Fereydoun, Huddleston John, Malig Maika, Nelson Bradley J., Sudmant Peter H., Parrish Nicholas F., Khurana Ekta, Hurles Matthew E., Blackburne Ben, Lindsay Sarah J., Ning Zemin, Walter Klaudia, Zhang Yujun, Gerstein Mark B., Abyzov Alexej, Chen Jieming, Clarke Declan, Lam Hugo, Jasmine Mu Xinmeng, Sisu Cristina, Zhang Jing, Zhang Yan, Gibbs Richard A., Yu Fuli, Bainbridge Matthew, Challis Danny, Evani Uday S., Kovar Christie, Lu James, Muzny Donna, Nagaswamy Uma, Reid Jeffrey G., Sabo Aniko, Yu Jin, Guo Xiaosen, Li Wangshen, Li Yingrui, Wu Renhua, Marth Gabor T., Garrison Erik P., Fung Leong Wen, Ward Alistair N., del Angel Guillermo, DePristo Mark A., Gabriel Stacey B., Gupta Namrata, Hartl Chris, Poplin Ryan E., Clark Andrew G., Rodriguez-Flores Juan L., Flicek Paul, Clarke Laura, Smith Richard E., Zheng-Bradley Xiangqun, MacArthur Daniel G., Mardis Elaine R., Fulton Robert, Koboldt Daniel C., Gravel Simon, Bustamante Carlos D., Craig David W., Christoforides Alexis, Homer Nils, Izatt Tyler, Sherry Stephen T., Xiao Chunlin, Dermitzakis Emmanouil T., Abecasis Gonçalo R., Min Kang Hyun, McVean Gil A., Gerstein Mark B., Balasubramanian Suganthi, Habegger Lukas, Yu Haiyuan, Flicek Paul, Clarke Laura, Cunningham Fiona, Dunham Ian, Zerbino Daniel, Zheng-Bradley Xiangqun, Lage Kasper, Berg Jespersen Jakob, Horn Heiko, Montgomery Stephen B., DeGorter Marianne K., Khurana Ekta, Tyler-Smith Chris, Chen Yuan, Colonna Vincenza, Xue Yali, Gerstein Mark B., Balasubramanian Suganthi, Fu Yao, Kim Donghoon, Auton Adam, Marcketta Anthony, Desalle Rob, Narechania Apurva, Wilson Sayres Melissa A., Garrison Erik P., Handsaker Robert E., Kashin Seva, McCarroll Steven A., Rodriguez-Flores Juan L., Flicek Paul, Clarke Laura, Zheng-Bradley Xiangqun, Erlich Yaniv, Gymrek Melissa, Frederick Willems Thomas, Bustamante Carlos D., Mendez Fernando L., David Poznik G., Underhill Peter A., Lee Charles, Cerveira Eliza, Malhotra Ankit, Romanovitch Mallory, Zhang Chengsheng, Abecasis Gonçalo R., Coin Lachlan, Shao Haojing, Mittelman David, Tyler-Smith Chris, Ayub Qasim, Banerjee Ruby, Cerezo Maria, Chen Yuan, Fitzgerald Thomas W., Louzada Sandra, Massaia Andrea, McCarthy Shane, Ritchie Graham R., Xue Yali, Yang Fengtang, Gibbs Richard A., Kovar Christie, Kalra Divya, Hale Walker, Muzny Donna, Reid Jeffrey G., Wang Jun, Dan Xu, Guo Xiaosen, Li Guoqing, Li Yingrui, Ye Chen, Zheng Xiaole, Altshuler David M., Flicek Paul, Clarke Laura, Zheng-Bradley Xiangqun, Bentley David R., Cox Anthony, Humphray Sean, Kahn Scott, Sudbrak Ralf, Albrecht Marcus W., Lienhard Matthias, Larson David, Craig David W., Izatt Tyler, Kurdoglu Ahmet A., Sherry Stephen T., Xiao Chunlin, Haussler David, Abecasis Gonçalo R., McVean Gil A., Durbin Richard M., Balasubramaniam Senduran, Keane Thomas M., McCarthy Shane, Stalker James, Bodmer Walter, Bedoya Gabriel, Ruiz-Linares Andres, Cai Zhiming, Gao Yang, Chu Jiayou, Peltonen Leena, Garcia-Montero Andres, Orfao Alberto, Dutil Julie, Martinez-Cruzado Juan C., Oleksyk Taras K., Barnes Kathleen C., Mathias Rasika A., Hennis Anselm, Watson Harold, McKenzie Colin, Qadri Firdausi, LaRocque Regina, Sabeti Pardis C., Zhu Jiayong, Deng Xiaoyan, Sabeti Pardis C., Asogun Danny, Folarin Onikepe, Happi Christian, Omoniwa Omonwunmi, Stremlau Matt, Tariyal Ridhi, Jallow Muminatou, Sisay Joof Fatoumatta, Corrah Tumani, Rockett Kirk, Kwiatkowski Dominic, Kooner Jaspal, Tịnh Hiê`n Trâ`n, Dunstan Sarah J., Thuy Hang Nguyen, Fonnie Richard, Garry Robert, Kanneh Lansana, Moses Lina, Sabeti Pardis C., Schieffelin John, Grant Donald S., Gallo Carla, Poletti Giovanni, Saleheen Danish, Rasheed Asif, A global reference for human genetic variation, 10.1038/nature15393
  11. Fumaz Carmina R., Tuldrà Albert, Ferrer Ma José, Paredes Roger, Bonjoch Anna, Jou Toni, Negredo Eugènia, Romeu Joan, Sirera Guillem, Tural Cristina, Clotet Bonaventura, Quality of Life, Emotional Status, and Adherence of HIV-1–Infected Patients Treated With Efavirenz Versus Protease Inhibitor–Containing Regimens : , 10.1097/00042560-200203010-00004
  12. Kenedi Christopher A., Goforth Harold W., A Systematic Review of the Psychiatric Side-Effects of Efavirenz, 10.1007/s10461-011-9939-5
  13. World Health Organization, Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach (2016)
  14. Marzolini Catia, Telenti Amalio, Decosterd Laurent A., Greub Gilbert, Biollaz Jérôme, Buclin Thierry, Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients : , 10.1097/00002030-200101050-00011
  15. Gallego Lucia, Barreiro Pablo, Rio Rafael del, Gonzalez de Requena Daniel, Rodriguez‐Albarino Apolinar, Gonzalez‐Lahoz Juan, Soriano Vincent, Analyzing Sleep Abnormalities in HIV‐Infected Patients Treated with Efavirenz, 10.1086/380791
  16. Csajka C, Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection, 10.1067/mcp.2003.22
  17. Gutierrez F, Clin Infect Dis, 54, 87 (2005)
  18. Ward B. A., The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity, 10.1124/jpet.103.049601
  19. Ogburn E. T., Jones D. R., Masters A. R., Xu C., Guo Y., Desta Z., Efavirenz Primary and Secondary Metabolism In Vitro and In Vivo: Identification of Novel Metabolic Pathways and Cytochrome P450 2A6 as the Principal Catalyst of Efavirenz 7-Hydroxylation, 10.1124/dmd.109.031393
  20. Mutlib AE, Drug Metab Dispos, 27, 1319 (1999)
  21. Haas DW, AIDS, 18, 2391 (2004)
  22. Rotger Margalida, Colombo Sara, Furrer Hansjakob, Bleiber Gabriela, Buclin Thierry, Lee Belle L., Keiser Olivia, Biollaz Jérôme, Décosterd Laurent, Telenti Amalio, Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients : , 10.1097/01213011-200501000-00001
  23. Ribaudo Heather J., Liu Huan, Schwab Matthias, Schaeffeler Elke, Eichelbaum Michel, Motsinger‐Reif Alison A., Ritchie Marylyn D., Zanger Ulrich M., Acosta Edward P., Morse Gene D., Gulick Roy M., Robbins Gregory K., Clifford David, Haas David W., Effect ofCYP2B6,ABCB1, andCYP3A5Polymorphisms on Efavirenz Pharmacokinetics and Treatment Response: An AIDS Clinical Trials Group Study, 10.1086/655470
  24. Gounden Verena, van Niekerk Chantal, Snyman Tracy, George Jaya A, Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients, 10.1186/1742-6405-7-32
  25. Gallien S, Journot V, Loriot M-A, Sauvageon H, Morlat P, Reynes J, Reliquet V, Chêne G, Molina J-M, , Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms : a substudy of the ANRS ALIZE trial, 10.1111/hiv.12488
  26. Rodriguez-Novoa S., Barreiro P., Rendon A., Jimenez-Nacher I., Gonzalez-Lahoz J., Soriano V., Influence of 516G>T Polymorphisms at the Gene Encoding the CYP450-2B6 Isoenzyme on Efavirenz Plasma Concentrations in HIV-Infected Subjects, 10.1086/429327
  27. Haas David W., Smeaton Laura M., Shafer Robert W., Robbins Gregory K., Morse Gene D., Labbé Line, Wilkinson Grant R., Clifford David B., D’Aquila Richard T., De Gruttola Victor, Pollard Richard B., Merigan Thomas C., Hirsch Martin S., George, Jr. Alfred L., Donahue John P., Kim Richard B., Pharmacogenetics of Long‐Term Responses to Antiretroviral Regimens Containing Efavirenz and/or Nelfinavir: An Adult AIDS Clinical Trials Group Study, 10.1086/497610
  28. Saitoh A, J Acquir Immune Defic Syndr, 45, 280 (2007)
  29. Sinxadi Phumla Z., Leger Paul D., McIlleron Helen M., Smith Peter J., Dave Joel A., Levitt Naomi S, Maartens Gary, Haas David W., Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa : Efavirenz pharmacokinetics in Cape Town, 10.1111/bcp.12590
  30. Wyen C., Hendra H., Vogel M., Hoffmann C., Knechten H., Brockmeyer N. H., Bogner J. R., Rockstroh J., Esser S., Jaeger H., Harrer T., Mauss S., van Lunzen J., Skoetz N., Jetter A., Groneuer C., Fatkenheuer G., Khoo S. H., Egan D., Back D. J., Owen A., , Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients, 10.1093/jac/dkn029
  31. Maimbo Milimo, Kiyotani Kazuma, Mushiroda Taisei, Masimirembwa Collen, Nakamura Yusuke, CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans, 10.1007/s00228-011-1118-0
  32. Mutwa Philippe R., Fillekes Quirine, Malgaz Marie, Tuyishimire Diane, Kraats Rianne van de, Boer Kimberly R., Burger David M., van Schaik Ron H. N., Muganga Narcisse, Geelen Sibyl P. M., Mid-Dosing Interval Efavirenz Plasma Concentrations in HIV-1–Infected Children in Rwanda : Treatment Efficacy, Tolerability, Adherence, and the Influence of CYP2B6 Polymorphisms, 10.1097/qai.0b013e3182569f57
  33. Dooley Kelly E., Denti Paolo, Martinson Neil, Cohn Silvia, Mashabela Fildah, Hoffmann Jennifer, Haas David W., Hull Jennifer, Msandiwa Regina, Castel Sandra, Wiesner Lubbe, Chaisson Richard E., Pharmacokinetics of Efavirenz and Treatment of HIV-1 Among Pregnant Women With and Without Tuberculosis Coinfection, 10.1093/infdis/jiu429
  34. Cortes Claudia P., Siccardi Marco, Chaikan Ammara, Owen Andrew, Zhang Guijun, Porte Charles J. L. la, Correlates of Efavirenz Exposure in Chilean Patients Affected With Human Immunodeficiency Virus Reveals a Novel Association With a Polymorphism in the Constitutive Androstane Receptor : , 10.1097/ftd.0b013e318274197e
  35. Ngaimisi Eliford, Habtewold Abiy, Minzi Omary, Makonnen Eyasu, Mugusi Sabina, Amogne Wondwossen, Yimer Getnet, Riedel Klaus-Dieter, Janabi Mohammed, Aderaye Getachew, Mugusi Ferdinand, Bertilsson Leif, Aklillu Eleni, Burhenne Juergen, Importance of Ethnicity, CYP2B6 and ABCB1 Genotype for Efavirenz Pharmacokinetics and Treatment Outcomes: A Parallel-Group Prospective Cohort Study in Two Sub-Saharan Africa Populations, 10.1371/journal.pone.0067946
  36. Bertrand Julie, Verstuyft Céline, Chou Monidarin, Borand Laurence, Chea Phalla, Nay Kuy Huong, Blanc François-Xavier, Mentré France, Taburet Anne-Marie, Sok Thim, Goldfeld Anne E., Blanc François-Xavier, Laureillard Didier, Marcy Olivier, Fernandez Marcelo, Chan Sarin, Nerrienet Eric, Vong Sirenda, Madec Yoann, Rekacewicz Claire, Saman Manil, Leng Chanthy, Ay Sao Sarady, Pheng Phearavin, Chan Lay Heng, Suom Sophea, Men Nimul Roat, Phon Kerya, Kun Sopheap, Chea Sokeo, Toeung Pichda, Yoeun Yong, Dy Keo Kunthea, Kry Pheakun, Meardey Keolinelyanneth, Guillard Bertrand, Srey Chanthan, Keo Chantary, Ngin Sopheak, Sar Borann, Nouhin Janin, Ken Sreymom, Chea Kimlay, Kong Kunthea, Tun Sophy, Say Leakhena, Sok Kim Eng, Lim Hok Kean, , Dependence of Efavirenz- and Rifampicin-Isoniazid–Based Antituberculosis Treatment Drug-Drug Interaction on CYP2B6 and NAT2 Genetic Polymorphisms: ANRS 12154 Study in Cambodia, 10.1093/infdis/jit466
  37. Mukonzo Jackson K., Röshammar Daniel, Waako Paul, Andersson Maria, Fukasawa Takashi, Milani Lili, Svensson Jan Olof, Ogwal-Okeng Jasper, Gustafsson Lars L., Aklillu Eleni, A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans : Efavirenz population pharmacokinetic/pharmacogenetic modelling, 10.1111/j.1365-2125.2009.03516.x
  38. Mukonzo Jackson K, Okwera Alphonse, Nakasujja Neoline, Luzze Henry, Sebuwufu Deogratious, Ogwal-Okeng Jasper, Waako Paul, Gustafsson Lars L, Aklillu Eleni, Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study, 10.1186/1471-2334-13-261
  39. Nyakutira Christopher, Röshammar Daniel, Chigutsa Emmanuel, Chonzi Prosper, Ashton Michael, Nhachi Charles, Masimirembwa Collen, High prevalence of the CYP2B6 516G→T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe, 10.1007/s00228-007-0412-3
  40. Carr D. F., la Porte C. J. L., Pirmohamed M., Owen A., Cortes C. P., Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort, 10.1093/jac/dkq260
  41. Bienvenu Emile, Swart Marelize, Dandara Collet, Ashton Michael, The role of genetic polymorphisms in cytochrome P450 and effects of tuberculosis co-treatment on the predictive value of CYP2B6 SNPs and on efavirenz plasma levels in adult HIV patients, 10.1016/j.antiviral.2013.11.011
  42. Meng Xianmin, Yin Kang, Wang Jiangrong, Dong Ping, Liu Li, Shen Yinzhong, Shen Li, Ma Qing, Lu Hongzhou, Cai Weimin, Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection, 10.1371/journal.pone.0130583
  43. Cusato Jessica, Tomasello Cristina, Simiele Marco, Calcagno Andrea, Bonora Stefano, Marinaro Letizia, Leggieri Anna, Allegra Sarah, Di Perri Giovanni, D’Avolio Antonio, Efavirenz pharmacogenetics in a cohort of Italian patients, 10.1016/j.ijantimicag.2015.11.012
  44. Orrell Catherine, Bienczak Andrzej, Cohen Karen, Bangsberg David, Wood Robin, Maartens Gary, Denti Paolo, Effect of mid-dose efavirenz concentrations and CYP2B6 genotype on viral suppression in patients on first-line antiretroviral therapy, 10.1016/j.ijantimicag.2016.03.017
  45. Hui KH, Lee SS, Lam TN, Dose Optimization of Efavirenz Based on Individual CYP2B6 Polymorphisms in Chinese Patients Positive for HIV : Genotype-Based Dose Optimizes Efavirenz Treatment, 10.1002/psp4.12067
  46. Luo Man, Chapel Sunny, Sevinsky Heather, Savant Ishani, Cirincione Brenda, Bertz Richard, Roy Amit, Population Pharmacokinetics Analysis To Inform Efavirenz Dosing Recommendations in Pediatric HIV Patients Aged 3 Months to 3 Years, 10.1128/aac.02678-15
  47. Nightingale Sam, Chau Tran Thi Hong, Fisher Martin, Nelson Mark, Winston Alan, Else Laura, Carr Daniel F., Taylor Steven, Ustianowski Andrew, Back David, Pirmohamed Munir, Solomon Tom, Farrar Jeremy, Törok M. Estée, Khoo Saye, Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship withCYP2B6c.516G→T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous Meningitis, 10.1128/aac.00280-16
  48. Liu Xia, Ma Qing, Zhao Yan, Mu Weiwei, Sun Xin, Cheng Yuewu, Zhang Huiping, Ma Ye, Zhang Fujie, Impact of Single Nucleotide Polymorphisms on Plasma Concentrations of Efavirenz and Lopinavir/Ritonavir in Chinese Children Infected with the Human Immunodeficiency Virus, 10.1002/phar.1988
  49. Viljoen M., Karlsson M. O., Meyers T. M., Gous H., Dandara C., Rheeders M., Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children, 10.1007/s00228-011-1148-7
  50. Lee Kuan-Yeh, Lin Shu-Wen, Sun Hsin-Yun, Kuo Ching-Hua, Tsai Mao-Song, Wu Bing-Ru, Tang Sue-Yo, Liu Wen-Chun, Chang Sui-Yuan, Hung Chien-Ching, Therapeutic Drug Monitoring and Pharmacogenetic Study of HIV-Infected Ethnic Chinese Receiving Efavirenz-Containing Antiretroviral Therapy with or without Rifampicin-Based Anti-Tuberculous Therapy, 10.1371/journal.pone.0088497
  51. Elens Laure, Vandercam Bernard, Yombi Jean-Cyr, Lison Dominique, Wallemacq Pierre, Haufroid Vincent, Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients, 10.2217/pgs.10.94
  52. Kwara Awewura, Lartey Margaret, Sagoe Kwamena WC, Kenu Ernest, Court Michael H, CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients : , 10.1097/qad.0b013e3283319908
  53. Gross Robert, Bellamy Scarlett L., Ratshaa Bakgaki, Han Xiaoyan, Vujkovic Marijana, Aplenc Richard, Steenhoff Andrew P., Mosepele Mosepele, Moorthy Ganesh, Zuppa Athena F., Strom Brian L., Bisson Gregory P., CYP2B6 genotypes and early efavirenz-based HIV treatment outcomes in Botswana : , 10.1097/qad.0000000000001593
  54. Holzinger Emily R., Grady Benjamin, Ritchie Marylyn D., Ribaudo Heather J., Acosta Edward P., Morse Gene D., Gulick Roy M., Robbins Gregory K., Clifford David B., Daar Eric S., McLaren Paul, Haas David W., Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants : , 10.1097/fpc.0b013e32835a450b
  55. Sarfo F. S., Zhang Y., Egan D., Tetteh L. A., Phillips R., Bedu-Addo G., Sarfo M. A., Khoo S., Owen A., Chadwick D. R., Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients, 10.1093/jac/dkt372
  56. Gandhi Monica, Greenblatt Ruth M., Bacchetti Peter, Jin Chengshi, Huang Yong, Anastos Kathryn, Cohen Mardge, DeHovitz Jack A., Sharp Gerald B., Gange Stephen J., Liu Chenglong, Hanson Susan C., Aouizerat Bradley, , A Single-Nucleotide Polymorphism in CYP2B6 Leads to >3-Fold Increases in Efavirenz Concentrations in Plasma and Hair Among HIV-Infected Women, 10.1093/infdis/jis508
  57. Wang J, Pharmacogenet Genomics, 13, 191 (2006)
  58. Dhoro Milcah, Zvada Simbarashe, Ngara Bernard, Nhachi Charles, Kadzirange Gerald, Chonzi Prosper, Masimirembwa Collen, CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe, 10.1186/s40360-015-0004-2
  59. Evans Jonathan, Swart Marelize, Soko Nyarai, Wonkam Ambroise, Huzair Farah, Dandara Collet, A Global Health Diagnostic for Personalized Medicine in Resource-Constrained World Settings: A Simple PCR-RFLP Method for Genotyping CYP2B6 g.15582C>T and Science and Policy Relevance for Optimal Use of Antiretroviral Drug Efavirenz, 10.1089/omi.2015.0039
  60. Bienczak Andrzej, Cook Adrian, Wiesner Lubbe, Olagunju Adeniyi, Mulenga Veronica, Kityo Cissy, Kekitiinwa Addy, Owen Andrew, Walker A. Sarah, Gibb Diana M., McIlleron Helen, Burger David, Denti Paolo, The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children : Efavirenz pharmacogenomics in African children, 10.1111/bcp.12934
  61. Heil Sandra G., van der Ende Marchina E., Schenk Paul W., van der Heiden Ilse, Lindemans Jan, Burger David, van Schaik Ron H. N., Associations Between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 Alleles in Relation to Efavirenz and Nevirapine Pharmacokinetics in HIV-Infected Individuals : , 10.1097/ftd.0b013e31824868f3
  62. Reay Riaan, Dandara Collet, Viljoen Michelle, Rheeders Malie, CYP2B6 Haplotype Predicts Efavirenz Plasma Concentration in Black South African HIV-1-Infected Children: A Longitudinal Pediatric Pharmacogenomic Study, 10.1089/omi.2017.0078
  63. ABDELHADY AHMED M., SHUGG TYLER, THONG NANCY, LU JESSICA BO LI, KREUTZ YVONNE, JAYNES HEATHER A., ROBARGE JASON D., TISDALE JAMES E., DESTA ZERUESENAY, OVERHOLSER BRIAN R., Efavirenz Inhibits the Human Ether-A-Go-Go Related Current (hERG) and Induces QT Interval Prolongation inCYP2B6*6*6Allele Carriers : Efavirenz Induced QTc Interval Prolongation, 10.1111/jce.13032
  64. Dickinson Laura, Amin Janaki, Else Laura, Boffito Marta, Egan Deirdre, Owen Andrew, Khoo Saye, Back David, Orrell Catherine, Clarke Amanda, Losso Marcelo, Phanuphak Praphan, Carey Dianne, Cooper David A., Emery Sean, Puls Rebekah, Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study, 10.1007/s40262-015-0360-5
  65. Aurpibul Linda, Chotirosniramit Nuntisa, Sugandhavesa Patcharaphan, Kosashunhanan Natthapol, Thetket Sunida, Supindham Taweewat, Piyamongkol Weerawit, Supparatpinyo Khuanchai, Correlation of CYP2B6-516G>T Polymorphism with Plasma Efavirenz Concentration and Depression in HIV-Infected Adults in Northern Thailand, 10.2174/157016212803901338
  66. Salem Ahmed Hamed, Fletcher Courtney V., Brundage Richard C., Pharmacometric Characterization of Efavirenz Developmental Pharmacokinetics and Pharmacogenetics in HIV-Infected Children, 10.1128/aac.01738-13
  67. Sánchez Almudena, Cabrera Salvador, Santos Dolores, Valverde M. Paz, Fuertes Aurelio, Domínguez-Gil Alfonso, García María J., , Population Pharmacokinetic/Pharmacogenetic Model for Optimization of Efavirenz Therapy in Caucasian HIV-Infected Patients, 10.1128/aac.00194-11
  68. Swart Marelize, Skelton Michelle, Ren Yuan, Smith Peter, Takuva Simbabrashe, Dandara Collet, High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients : , 10.1097/fpc.0b013e328363176f
  69. Gengiah Tanuja N, Botha Julia H, Yende-Zuma Nonhlanhla, Naidoo Kogieleum, Abdool Karim Salim S, Efavirenz dosing: influence of drug metabolizing enzyme polymorphisms and concurrent tuberculosis treatment, 10.3851/imp2877
  70. Burger David, van der Heiden Ilse, la Porte Charles, van der Ende Marchina, Groeneveld Paul, Richter Clemens, Koopmans Peter, Kroon Frank, Sprenger Herman, Lindemans Jan, Schenk Paul, van Schaik Ron, Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism, 10.1111/j.1365-2125.2005.02536.x
  71. Yimer G, Amogne W, Habtewold A, Makonnen E, Ueda N, Suda A, Worku A, Haefeli W E, Burhenne J, Aderaye G, Lindquist L, Aklillu E, High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort study, 10.1038/tpj.2011.34
  72. Fellay Jacques, Marzolini Catia, Meaden Emma R, Back David J, Buclin Thierry, Chave Jean-Philippe, Decosterd Laurent A, Furrer Hansjakob, Opravil Milos, Pantaleo Giuseppe, Retelska Dorota, Ruiz Lidia, Schinkel Alfred H, Vernazza Pietro, Eap Chin B, Telenti Amalio, Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study, 10.1016/s0140-6736(02)07276-8
  73. Mukonzo Jackson K., Owen Joel S., Ogwal-Okeng Jasper, Kuteesa Ronald B., Nanzigu Sarah, Sewankambo Nelson, Thabane Lehana, Gustafsson Lars L., Ross Colin, Aklillu Eleni, Pharmacogenetic-Based Efavirenz Dose Modification: Suggestions for an African Population and the Different CYP2B6 Genotypes, 10.1371/journal.pone.0086919
  74. Haas David W., Severe Patrice, Jean Juste Marc Antoine, Pape Jean William, Fitzgerald Daniel W., Functional CYP2B6 variants and virologic response to an efavirenz-containing regimen in Port-au-Prince, Haiti, 10.1093/jac/dku088
  75. Arab-Alameddine M, Di Iulio J, Buclin T, Rotger M, Lubomirov R, Cavassini M, Fayet A, Décosterd LA, Eap CB, Biollaz J, Telenti A, Csajka C, Pharmacogenetics-Based Population Pharmacokinetic Analysis of Efavirenz in HIV-1-Infected Individuals, 10.1038/clpt.2008.271
  76. Lubomirov Rubin, Colombo Sara, di Iulio Julia, Ledergerber Bruno, Martinez Raquel, Cavassini Matthias, Hirschel Bernard, Bernasconi Enos, Elzi Luigia, Vernazza Pietro, Furrer Hansjakob, Günthard Huldrych F., Telenti Amalio, , Association of Pharmacogenetic Markers with Premature Discontinuation of First-line Anti-HIV Therapy: An Observational Cohort Study, 10.1093/infdis/jiq043
  77. Cummins Nathan W., Neuhaus Jacqueline, Chu Haitao, Neaton James, Wyen Christoph, Rockstroh Jürgen K., Skiest Daniel J., Boyd Mark A., Khoo Saye, Rotger Margalida, Telenti Amalio, Weinshilboum Richard, Badley Andrew D., Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis, 10.1016/j.ebiom.2015.05.012
  78. Frasco Melissa A., Mack Wendy J., Van Den Berg David, Aouizerat Bradley E., Anastos Kathryn, Cohen Mardge, De Hovitz Jack, Golub Elizabeth T., Greenblatt Ruth M., Liu Chenglong, Conti David V., Pearce Celeste L., Underlying genetic structure impacts the association between CYP2B6 polymorphisms and response to efavirenz and nevirapine : , 10.1097/qad.0b013e3283593602
  79. Mollan Katie R, Tierney Camlin, Hellwege Jacklyn N, Eron Joseph J, Hudgens Michael G, Gulick Roy M, Haubrich Richard, Sax Paul E, Campbell Thomas B, Daar Eric S, Robertson Kevin R, Ventura Diana, Ma Qing, Edwards Digna R. Velez, Haas David W, , Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants, 10.1093/infdis/jix248
  80. Gatanaga H., Hayashida T., Tsuchiya K., Yoshino M., Kuwahara T., Tsukada H., Fujimoto K., Sato I., Ueda M., Horiba M., Hamaguchi M., Yamamoto M., Takata N., Kimura A., Koike T., Gejyo F., Matsushita S., Shirasaka T., Kimura S., Oka S., Successful Efavirenz Dose Reduction in HIV Type 1-Infected Individuals with Cytochrome P450 2B6 *6 and *26, 10.1086/522175
  81. Martín Almudena Sánchez, Gómez Alicia Iglesias, García-Berrocal Belén, Figueroa Salvador Cabrera, Sánchez Miguel Cordero, Calvo Hernández María Victoria, Gonzalez-Buitrago Jose Manuel, Valverde Merino María Paz, Tovar Carmen Bustos, Martín Aurelio Fuertes, Isidoro-García María, Dose reduction of efavirenz: an observational study describing cost–effectiveness, pharmacokinetics and pharmacogenetics, 10.2217/pgs.14.48
  82. Schackman Bruce R, Haas David W, Park Sanghee S, Li X Cynthia, Freedberg Kenneth A, Cost–effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice, 10.2217/pgs.15.142
  83. Olagunju Adeniyi, Schipani Alessandro, Bolaji Oluseye, Khoo Saye, Owen Andrew, Evaluation of universal versus genotype-guided efavirenz dose reduction in pregnant women using population pharmacokinetic modelling, 10.1093/jac/dkx334
  84. Sanne Ian, Mommeja‐Marin Herve, Hinkle John, Bartlett John A., Lederman Michael M., Maartens Gary, Wakeford Charles, Shaw Audrey, Quinn Joseph, Gish Robert G., Rousseau Franck, Severe Hepatotoxicity Associated with Nevirapine Use in HIV‐Infected Subjects, 10.1086/428093
  85. de Vries-Sluijs Theodora E M S, Dieleman Jeanne P, Arts Dennis, Huitema Alwin D R, Beijnen Jos H, Schutten Martin, van der Ende Marchina E, Low Nevirapine Plasma Concentrations Predict Virological Failure in an Unselected HIV-1-Infected Population : , 10.2165/00003088-200342060-00009
  86. Veldkamp Agnes I., Weverling Gerrit J., Lange Joep M. A., Montaner Julio S. G., Reiss Peter, Cooper David A., Vella Stefano, Hall David, Beijnen Jos H., Hoetelmans Richard M. W., High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals : , 10.1097/00002030-200106150-00003
  87. Erickson DA, Drug Metab Dispos, 27, 1488 (1999)
  88. Riska P, Drug Metab Dispos, 27, 895 (1999)
  89. Dickinson Laura, Chaponda Masautso, Carr Daniel F., van Oosterhout Joep J., Kumwenda Johnstone, Lalloo David G., Pirmohamed Munir, Heyderman Robert S., Khoo Saye H., Population Pharmacokinetic and Pharmacogenetic Analysis of Nevirapine in Hypersensitive and Tolerant HIV-Infected Patients from Malawi, 10.1128/aac.02069-13
  90. Mahungu TW, Smith CJ, Turner F, Egan D, Youle M, Johnson MA, Khoo S, Back DJ, Owen A, Cytochrome P450 2B6 516G→T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population, 10.1111/j.1468-1293.2008.00689.x
  91. Schipani A., Wyen C., Mahungu T., Hendra H., Egan D., Siccardi M., Davies G., Khoo S., Fatkenheuer G., Youle M., Rockstroh J., Brockmeyer N. H., Johnson M. A., Owen A., Back D. J., , Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals, 10.1093/jac/dkr087
  92. Calcagno Andrea, D'Avolio Antonio, Simiele Marco, Cusato Jessica, Rostagno Roberto, Libanore Valentina, Baietto Lorena, Siccardi Marco, Bonora Stefano, Di Perri Giovanni, Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices : Dried spots-based pharmacogenetics of nevirapine, 10.1111/j.1365-2125.2012.04163.x
  93. Mhandire Doreen, Lacerda Miguel, Castel Sandra, Mhandire Kudakwashe, Zhou Danai, Swart Marelize, Shamu Tinei, Smith Peter, Musingwini Tutsirai, Wiesner Lubbe, Stray-Pedersen Babill, Dandara Collet, Effects of CYP2B6 and CYP1A2 Genetic Variation on Nevirapine Plasma Concentration and Pharmacodynamics as Measured by CD4 Cell Count in Zimbabwean HIV-Infected Patients, 10.1089/omi.2015.0104
  94. Oluka Margaret Ngwono, Okalebo Faith Apolot, Guantai Anastasia Nkatha, McClelland R Scott, Graham Susan M, Cytochrome P450 2B6 genetic variants are associated with plasma nevirapine levels and clinical response in HIV-1 infected Kenyan women: a prospective cohort study, 10.1186/s12981-015-0052-0
  95. Bienczak Andrzej, Cook Adrian, Wiesner Lubbe, Mulenga Veronica, Kityo Cissy, Kekitiinwa Addy, Walker A. Sarah, Owen Andrew, Gibb Diana M., Burger David, McIlleron Helen, Denti Paolo, Effect of diurnal variation,CYP2B6genotype and age on the pharmacokinetics of nevirapine in African children, 10.1093/jac/dkw388
  96. Guidi M., Arab-Alameddine Mona, Rotger Margalida, Aouri Manel, Telenti Amalio, Decosterd Laurent A., Buclin Thierry, Csajka Chantal, Dosage Optimization of Treatments Using Population Pharmacokinetic Modeling and Simulation, 10.2533/chimia.2012.291
  97. Saitoh Akihiko, Sarles Elizabeth, Capparelli Edmund, Aweeka Francesca, Kovacs Andrea, Burchett Sandra K, Wiznia Andrew, Nachman Sharon, Fenton Terence, Spector Stephen A, CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children : , 10.1097/qad.0b013e3282ef9695
  98. Lehr Thorsten, Yuan Jing, Hall David, Zimdahl-Gelling Heike, Schaefer Hans Guenter, Staab Alexander, MacGregor Thomas R., Jayadev Supriya, Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine : , 10.1097/fpc.0b013e32834a522e
  99. Olagunju Adeniyi, Bolaji Oluseye, Neary Megan, Back David, Khoo Saye, Owen Andrew, Pregnancy affects nevirapine pharmacokinetics : evidence from a CYP2B6 genotype-guided observational study, 10.1097/fpc.0000000000000227
  100. Gozalo Claire, Gérard Laurence, Loiseau Pascale, Morand-Joubert Laurence, Peytavin Gilles, Molina Jean-Michel, Dellamonica Pierre, Becquemont Laurent, Aboulker Jean-Pierre, Launay Odile, Verstuyft Céline, , Pharmacogenetics of Toxicity, Plasma Trough Concentration and Treatment Outcome with Nevirapine-Containing Regimen in Anti-Retroviral-Naïve HIV-Infected Adults: An Exploratory Study of the TRIANON ANRS 081 Trial : PHARMACOGENETICS AND NEVIRAPINE, 10.1111/j.1742-7843.2011.00780.x
  101. Haas David W., Gebretsadik Tebeb, Mayo Gail, Menon Usha N., Acosta Edward P., Shintani Ayumi, Floyd Michael, Stein C. Michael, Wilkinson Grant R., Associations betweenCYP2B6Polymorphisms and Pharmacokinetics after a Single Dose of Nevirapine or Efavirenz in African Americans, 10.1086/597125
  102. Yuan Jing, Guo Sheng, Hall David, Cammett Anna M, Jayadev Supriya, Distel Manuel, Storfer Stephen, Huang Zimei, Mootsikapun Piroon, Ruxrungtham Kiat, Podzamczer Daniel, Haas David W, Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent : , 10.1097/qad.0b013e32834779df
  103. Ciccacci Cinzia, Di Fusco Davide, Marazzi Maria C., Zimba Ines, Erba Fulvio, Novelli Giuseppe, Palombi Leonardo, Borgiani Paola, Liotta Giuseppe, Association between CYP2B6 polymorphisms and Nevirapine-induced SJS/TEN: a pharmacogenetics study, 10.1007/s00228-013-1549-x
  104. Haas D. W., Bartlett J. A., Andersen J. W., Sanne I., Wilkinson G. R., Hinkle J., Rousseau F., Ingram C. D., Shaw A., Lederman M. M., Kim R. B., , Pharmacogenetics of Nevirapine-Associated Hepatotoxicity: An Adult AIDS Clinical Trials Group Collaboration, 10.1086/507097
  105. Carr D. F., Chaponda M., Cornejo Castro E. M., Jorgensen A. L., Khoo S., Van Oosterhout J. J., Dandara C., Kampira E., Ssali F., Munderi P., Lalloo D. G., Heyderman R. S., Pirmohamed M., CYP2B6 c.983T>C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populations, 10.1093/jac/dku315
  106. Aouri Manel, Barcelo Catalina, Guidi Monia, Rotger Margalida, Cavassini Matthias, Hizrel Cédric, Buclin Thierry, Decosterd Laurent A., Csajka Chantal, , Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals, 10.1128/aac.00899-16
  107. Kile Deidre A., MaWhinney Samantha, Aquilante Christina L., Rower Joseph E., Castillo-Mancilla Jose R., Anderson Peter L., A Population Pharmacokinetic-Pharmacogenetic Analysis of Atazanavir, 10.1089/aid.2011.0378
  108. Savic R M, Barrail-Tran A, Duval X, Nembot G, Panhard X, Descamps D, Verstuyft C, Vrijens B, Taburet A-M, Goujard C, Mentré F, Effect of Adherence as Measured by MEMS, Ritonavir Boosting, and CYP3A5 Genotype on Atazanavir Pharmacokinetics in Treatment-Naive HIV-Infected Patients, 10.1038/clpt.2012.137
  109. Castillo-Mancilla Jose R., Aquilante Christina L., Wempe Michael F., Smeaton Laura M., Firnhaber Cynthia, LaRosa Alberto M., Kumarasamy Nagalingeswaran, Andrade Adriana, Baheti Gautam, Fletcher Courtney V., Campbell Thomas B., Haas David W., MaWhinney Samantha, Anderson Peter L., Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342), 10.1093/jac/dkw005
  110. D'Avolio A., Carcieri C., Cusato J., Simiele M., Calcagno A., Allegra S., Sciandra M., Trentini L., Di Perri G., Bonora S., Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms, 10.1093/jac/dku234
  111. Johnson Daniel H., Venuto Charles, Ritchie Marylyn D., Morse Gene D., Daar Eric S., McLaren Paul J., Haas David W., Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202 : , 10.1097/fpc.0000000000000034
  112. Gammal RS, Court MH, Haidar CE, Iwuchukwu OF, Gaur AH, Alvarellos M, Guillemette C, Lennox JL, Whirl-Carrillo M, Brummel SS, Ratain MJ, Klein TE, Schackman BR, Caudle KE, Haas DW, Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline forUGT1A1and Atazanavir Prescribing, 10.1002/cpt.269
  113. Vermeir M., Lachau-Durand S., Mannens G., Cuyckens F., van Hoof B., Raoof A., Absorption, Metabolism, and Excretion of Darunavir, a New Protease Inhibitor, Administered Alone and with Low-Dose Ritonavir in Healthy Subjects, 10.1124/dmd.108.024109
  114. Sekar V, XVI International AIDS Conference (2006)
  115. Arab-Alameddine M., Lubomirov R., Fayet-Mello A., Aouri M., Rotger M., Buclin T., Widmer N., Gatri M., Ledergerber B., Rentsch K., Cavassini M., Panchaud A., Guidi M., Telenti A., Décosterd L. A., Csajka C., Battegay M., Bernasconi E., Böni J., Bucher H. C., Bürgisser P., Calmy A., Cattacin S., Cavassini M., Dubs R., Egger M., Elzi L., Fischer M., Flepp M., Fontana A., Francioli P., Furrer H., Fux C. A., Gorgievski M., Günthard H., Hirsch H. H., Hirschel B., Hösli I., Kahlert C., Kaiser L., Karrer U., Kind C., Klimkait T., Ledergerber B., Martinetti G., Müller N., Nadal D., Paccaud F., Pantaleo G., Rauch A., Regenass S., Rickenbach M., Rudin C., Schmid P., Schultze D., Schüpbach J., Speck R., de Tejada B. M., Taffé P., Telenti A., Trkola A., Vernazza P., Weber R., Yerly S., , Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals, 10.1093/jac/dku131
  116. Belkhir Leïla, Elens Laure, Zech Francis, Panin Nadtha, Vincent Anne, Yombi Jean Cyr, Vandercam Bernard, Haufroid Vincent, Interaction between Darunavir and Etravirine Is Partly Mediated by CYP3A5 Polymorphism, 10.1371/journal.pone.0165631
  117. Lubomirov R, Pharmacogenet Genomics, 20, 217 (2010)
  118. Elens Laure, Yombi Jean-Cyr, Lison Dominique, Wallemacq Pierre, Vandercam Bernard, Haufroid Vincent, Association betweenABCC2polymorphism and lopinavir accumulation in peripheral blood mononuclear cells of HIV-infected patients, 10.2217/pgs.09.88
  119. Mpeta Bafokeng, Kampira Elizabeth, Castel Sandra, Mpye Keleabetswe L, Soko Nyarai D, Wiesner Lubbe, Smith Peter, Skelton Michelle, Lacerda Miguel, Dandara Collet, Differences in genetic variants in lopinavir disposition among HIV-infected Bantu Africans, 10.2217/pgs.16.14
  120. Estrela RCE, Santoro AB, Barroso PF, Tuyama M, Suarez-Kurtz G, CYP3A5 Genotype Has No Impact on Plasma Trough Concentrations of Lopinavir and Ritonavir in HIV-infected Subjects, 10.1038/clpt.2008.12
  121. Rakhmanina Natella Y, Neely Michael N, Van Schaik Ron HN, Gordish-Dressman Heather A, Williams Keetra D, Soldin Steven J, van den Anker John N, CYP3A5, ABCB1, and SLCO1B1 Polymorphisms and Pharmacokinetics and Virologic Outcome of Lopinavir/Ritonavir in HIV-Infected Children : , 10.1097/ftd.0b013e318225384f
  122. Zhang Xinyan, Tierney Camlin, Albrecht Mary, Demeter Lisa M., Morse Gene, DiFrancesco Robin, Dykes Carrie, Jiang Hongyu, Haas David W., Discordant Associations Between SLCO1B1 521T→C and Plasma Levels of Ritonavir-boosted Protease Inhibitors in AIDS Clinical Trials Group Study A5146 : , 10.1097/ftd.0b013e318280d0ad
  123. Olagunju Adeniyi, Schipani Alessandro, Siccardi Marco, Egan Deirdre, Khoo Saye, Back David, Owen Andrew, CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults : , 10.1097/fpc.0000000000000073
  124. Hughes Dyfrig A, Vilar F Javier, Ward Charlotte C, Alfirevic Ana, Park B Kevin, Pirmohamed Munir, Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity : , 10.1097/00008571-200406000-00002
  125. Ziagen® [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2008.
Bibliographic reference Stillemans, Gabriel ; Belkhir, Leïla ; Hesselink, Dennis A ; Haufroid, Vincent ; Elens, Laure. Pharmacogenetic associations with cytochrome P450 in antiretroviral therapy: what does the future hold?. In: Expert opinion on drug metabolism & toxicology, Vol. 14, no. 6, p. 601-611 (2018)
Permanent URL http://hdl.handle.net/2078.1/210415